We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

6 hedge funds and large institutions have $368K invested in Hepion Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

40% less funds holding

Funds holding: 10 → 6 (-4)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

62% less capital invested

Capital invested by funds: $957K → $368K (-$589K)

Holders
6
Holders Change
-4
Holders Change %
-40%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$292K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$132K
3
PFS
Prospera Financial Services
Texas
+$87.9K
4
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management
Wisconsin
+$28K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$231K
2
OAM
Oxford Asset Management
United Kingdom
-$92K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$74K
4
Deutsche Bank
Deutsche Bank
Germany
-$37K
5
UBS Group
UBS Group
Switzerland
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$128K +$292K +73 New
BlackRock
2
BlackRock
New York
$107K – – –
PFS
3
Prospera Financial Services
Texas
$62K +$87.9K +22 +169%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$58K +$132K +33 New
Northwestern Mutual Wealth Management
5
Northwestern Mutual Wealth Management
Wisconsin
$12K +$28K +7 New
Morgan Stanley
6
Morgan Stanley
New York
$1K -$12K -3 -75%
Renaissance Technologies
7
Renaissance Technologies
New York
– -$231K -43 Closed
OAM
8
Oxford Asset Management
United Kingdom
– -$92K -17 Closed
Geode Capital Management
9
Geode Capital Management
Massachusetts
– -$74K -14 Closed
Deutsche Bank
10
Deutsche Bank
Germany
– -$37K -7 Closed
UBS Group
11
UBS Group
Switzerland
– -$18K -3 Closed
APA
12
American Portfolios Advisors
New York
– -$10.7K -2 Closed

HEPA Hedge Fund Activity: Q1 2020 in Review

6 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2020, worth a combined $368K — down 62% from $957K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of HEPA and 3 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $292K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $231K sold.

  • 6 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2020, down from 10 in Q4 2019.
  • Funds reported $368K of Hepion Pharmaceuticals stock for Q1 2020, down 62% quarter-over-quarter.
  • 3 funds opened new Hepion Pharmaceuticals positions in Q1 2020 and 6 closed out, a net change of -3 holders.
  • The largest Hepion Pharmaceuticals buyer in Q1 2020 was Sabby Management, an estimated $292K added.
  • The largest Hepion Pharmaceuticals seller in Q1 2020 was Renaissance Technologies, an estimated $231K sold.

Based on aggregated 13F filings for Q1 2020.